BIOM30001 Lecture 23: 23a Biological therapies for respiratory disease B
Document Summary
Il-13 elicits changes in airway epithelium - produces fibrogenic factors like tgfb and periostin (matrix molecule) Serum periostin used as a biomarker of il 1(cid:1007) a(cid:272)ti(cid:448)ity o(cid:374) epitheliu(cid:373) These people (10%) don"t respond well to traditional therapy. Not fully controlled by laba/ics +/- cyslt1 blocker. Therapies should have either a steroid sparing profile or activity that complements steroid actions. Fab fragments co-crystalised with il-13: allow visualisation to find where on the target molecule mab binds. Gives understanding of steric implications of interaction between. Mutations changing single amino acids - influence on binding. O(cid:448)erlay sho(cid:449)s il1(cid:1007) u(cid:374)a(cid:271)le to (cid:271)i(cid:374)d il (cid:1008)ra a(cid:374)d fa(cid:271) at sa(cid:373)e ti(cid:373)e. Studies useful when target has multiple binding partners. There is a subgroup of asthma patients who might benefit from neutralising il-13. At baseline: fev1 65% predicted (high periostin group had 73%), on 580ug ics/80% laba. High periostin: + 12% fev1 (more likely to respond to anti il-13 )
